BioNTech vs Halozyme Therapeutics
BNTX and HALO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BNTX and HALO compare
Halozyme Therapeutics grew revenue faster over the last twelve months (45.0% versus 4.3% for BioNTech).
Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 26.9% compared with −39.6% at BioNTech.
Halozyme Therapeutics scores higher on the StockData Score (13 against 3 for BioNTech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BNTX | HALO |
|---|---|---|
| Size and price | ||
| Market cap | – | $11.4B |
| Share price | $85.60 | $100.27 |
| Change, 1 year | −23.4% | 42.0% |
| Change, 5 years | −70.5% | 182% |
| Beta (5Y) | 0.81 | 0.74 |
| Employees | 500 | 423 |
| StockData Score | ||
| Total score | 3 | 13 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 1 | 5 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 25.3× |
| P/S | – | 6.3× |
| EV/EBITDA | – | 19.7× |
| P/FCF | – | 12.8× |
| PEG | – | 1.19 |
| FCF yield | – | 7.8% |
| Fair value | – | $83.32 |
| Margin of safety | – | −20.3% |
| Growth | ||
| Revenue growth (TTM) | 4.3% | 45.0% (better) |
| Revenue growth, 5Y average | 42.9% (better) | 39.2% |
| Net income growth (TTM) | – | −18.5% |
| EPS growth (TTM) | – | −16.4% |
| EPS growth, 5Y average | – | 23.0% |
| Profitability | ||
| Gross margin | 77.6% | 82.3% (better) |
| Operating margin | −49.0% | 37.4% (better) |
| Net margin | −39.6% | 26.9% (better) |
| FCF margin | 9.8% | 49.1% (better) |
| Return on equity | – | 216% |
| Return on invested capital | – | 26.6% |
| Financial health | ||
| Net debt / EBITDA | – | 3.21 |
| Interest coverage | −20.1× | 30.6× (better) |
| Current ratio | 7.54 (better) | 3.88 |
| Altman Z-score | – | 3.54 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 18.9% | 109% |
| Held by insiders | 58.2% | 1.3% |
| Insider net buying, 12 months | −$89.8M | −$43.8M (better) |
| Short interest, % of float | – | 12.2% |
Go deeper
- BNTX stock overview
- BNTX income statement
- BNTX valuation and score
- HALO stock overview
- HALO income statement
- HALO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.